

25 **Abstract**

26 **Background:** The 15q13.3 microdeletion has pleiotropic effects ranging from
27 apparently healthy to severely affected individuals. The underlying basis of the variable
28 phenotype remains elusive.

29 **Methods:** We analyzed gene expression using blood from 3 individuals with 15q13.3
30 microdeletion and brain cortex tissue from 10 mice Df[h15q13]/+. We assessed differentially
31 expressed genes (DEGs), protein-protein interaction (PPI) functional modules, and gene
32 expression in brain developmental stages.

33 **Results:** The deleted genes' haploinsufficiency was not transcriptionally compensated,
34 suggesting a dosage effect may contribute to the pathomechanism. DEGs shared between
35 tested individuals and a corresponding mouse model show a significant overlap including
36 genes involved in monogenic neurodevelopmental disorders. Yet, network-wide
37 dysregulatory effects suggest the phenotype is not caused by a singular critical gene. A
38 significant proportion of blood DEGs, silenced in adult brain, have maximum expression
39 during the prenatal brain development. Based on DEGs and their PPI partners we identified
40 altered functional modules related to developmental processes, including nervous system
41 development.

42 **Conclusions:** We show that the 15q13.3 microdeletion has a ubiquitous impact on the
43 transcriptome pattern, especially dysregulation of genes involved in brain development. The
44 high phenotypic variability seen in 15q13.3 microdeletion could stem from an increased
45 vulnerability during brain development, instead of a specific pathomechanism.

46 **Keywords:** 15q13.3; Copy number variants; Transcriptomics; Protein-protein
47 interaction networks; Nervous System Development.

48 **Introduction**

49 Individuals with 15q13.3 microdeletion (OMIM #612001) show clinical
50 manifestations ranging from no obvious symptoms to severe intellectual disability,
51 neuropsychiatric disorders, and epilepsy¹ (Fig. 1 A, B). The most common 15q13.3 deletion
52 spans 2 Mb and includes eight RefSeq genes (*CHRNA7*, *FAN1*, *TRPM1*, *KLF13*, *OTUD7A*,
53 *MTMR10*, *ARHGAP11B*, and *MIR211*, Fig. 1A)². Many functional and association studies
54 inquired which gene(s) encompassed by the deleted region could be responsible for the
55 phenotype. However, the results were as variable as the clinical manifestation and different
56 groups proposed multiple candidates (*CHRNA7*^{3,4}, *OTUD7A*^{5,6}, *FAN1*⁷, *ARHGAP11B*⁸,
57 *TRPM1*⁹, *KLF13*¹⁰), to explain the symptoms (Fig. 1A). A mouse model of the 15q13.3
58 microdeletion syndrome (Df[h15q13]/+) shows manifestations similar to affected humans
59 ranging from attention deficits to impaired behavior and disrupted prefrontal cortex
60 processing¹¹. Thus, the microdeletion effect is stable across species and clearly impairs
61 nervous system function.

62 Recently, it was suggested that many disrupted biological pathways such as Wnt
63 signaling or ribosome biogenesis may be involved in the molecular mechanism underlying the
64 disease rather than singular dosage-affected genes¹². While Zhang *et al.* used a multiomics
65 approach to identify perturbed biological processes, the multiple employed analyses showed
66 disagreement with respect to the pathomechanism. Also, no shared dysregulated genes were
67 identified between human induced pluripotent stem cells (iPSCs) and mouse cortex¹². This
68 could be a result of the *in vitro* setup and neuronal differentiation protocols, which generally
69 impact gene expression profiles¹³. We thus sought to inquire gene expression profiles in
70 subjects with 15q13.3 microdeletion in a native/*in vivo* state.

71 One major challenge of transcriptomics in a clinical setting is tissue-specific gene
72 expression^{14,15} and the fact that most of the times the only accessible tissue to probe is blood
73¹⁶. In our previous work we showed, however, that known genes for neurodevelopmental
74 disorders are not necessarily expressed in the adult brain and that genes which are relevant
75 during embryonic development of the central nervous system can be silenced at a later
76 timepoint¹⁴. Thus, although not regarded as a representative tissue, blood transcriptomics has
77 the potential to reveal aspects missed in other tissues or iPSCs.

78 In the present study, we analyzed the changes in gene expression profiles in the blood
79 of three individuals with heterozygous microdeletion 15q13.3 and intellectual disability
80 associated with epilepsy. We identified a significant overlap (p -value = 0.02) of 68

81 differentially expressed genes (DEGs) between humans and mouse (*Df[h15q13]/+*) cortex.
82 The gene ontology (GO) category most significantly enriched with DEGs was “nervous
83 system development–GO:0007399” and DEGs in blood, which are not expressed in the adult
84 brain, revealed maximum expression levels in the prenatal stage of brain development. The
85 disrupted gene expression profile could lead to an increased vulnerability in the early stages
86 of nervous system development.

87 **Materials and Methods**

88 *Ethics approval*

89 This study was approved and monitored by the ethics committee of the University of
90 Leipzig, Germany (224/16-ek and 402/16-ek).

91 *Chr15q13.2q13.3 microdeletion individuals and mouse model (Df[h15q13]/+)*

92 Three individuals with diagnosed heterozygous 15q13.2q13.3 microdeletions were
93 previously described¹⁷. For all individuals we performed Illumina TruSight One Panel and
94 microarray analysis. Patient 1 is a male with a deletion of 2.56 Mbp
95 (15q13.2q13.3(30366247_32927476)x1). The second patient is female and carries a deletion
96 on chromosome 15 of 1.57 Mbp (15q13.2q13.3(30936285_32514341)x1). Patient 3 is a male,
97 has a deletion of 2.14 Mbp on chromosome 15 (15q13.2q13.3(30371774_32514341)x1). He
98 was additionally diagnosed with a maternally inherited splicing-variant in the remaining
99 *TRPM1* allele and a heterozygous *de novo* point mutation in *MITF*. Pathogenic variants in
100 *MITF* gene cause albinism, which was also clinically diagnosed in this individual. His
101 ophthalmological phenotype (severe myopia, astigmatism, and pendular nystagmus) were
102 clinical symptoms of the autosomal recessive *TRPM1* phenotype (one allele being deleted as
103 part of the 15q13.3 microdeletion and the other allele carrying the maternally inherited
104 splicing variant). In sum, he suffered from a complex combined phenotype with neurologic
105 symptoms attributed to the 15q13.3 microdeletion. Blood RNA samples were taken from the
106 three individuals (two males and one female, aged 27–63 years) and four control subjects
107 (two males and two females, aged 20–52 years).

108 To identify molecular changes which are consistent across species we used the data
109 generated by Gordon and colleagues (GSE129891)¹⁸. We analyzed transcriptomes from
110 cerebral cortex tissue of mice with heterozygous deletions on mouse chromosome 7qC
111 syntenic to human 15q13.3^{11,18}.

112 ***RNA extraction and sequencing***

113 RNA was extracted from PAXgene blood samples using PAXgene Blood RNA Kit
114 (Qiagen). RNA sequencing (RNA-seq) libraries were prepared using TruSeq RNA Library
115 Prep Kit v2 (Illumina, San Diego, CA) and sequenced on an Illumina NovaSeq platform with
116 151 bp paired-end reads.

117 ***Differential Gene Expression (DEG) analysis***

118 RNA-seq reads were mapped to the human genome assembly hg38 with STAR
119 (version 2.6.1d)¹⁹. We computed the transcript levels with htseq-count (version 0.6.0)²⁰.
120 From GSE129891 we analyzed read counts of ten wild type and ten (Df[h15q13]/+) mouse
121 cerebral cortex samples. Genes with a sum of less than 10 reads in all samples together were
122 excluded from further analysis. Differential expression of genes was determined with the R
123 package DESeq2 (version 1.30.1)²¹, which uses the Benjamini-Hochberg method to correct
124 for multiple testing²². Genes were considered to be significantly differentially expressed if p -
125 adj < 0.05. To check clustering of RNA-sequencing samples of subjects and controls, a
126 principal component analysis (PCA) was performed with the R package pcaExplorer (version
127 2.6.0)²³. RNA count data were variance stabilized transformed and the 500 most variant
128 genes (top n genes) were selected for computing the principal components.

129 ***Expression of DEGs in different developmental stages***

130 Expression data of DEGs were obtained from PTEE (version 1.1)¹⁴ for the adult brain
131 cortex. Genes expressed at a low level in adult brain tissue may be expressed at a higher level
132 in the developing brain and therefore, could still play a significant role in neurodevelopment.
133 Hence, for DEGs expressed <1.5 TPM in adult brain cortex (according to PTEE), expression
134 levels in different developmental stages were obtained from the R package ABAEnrichment
135 (version 1.20.0)²⁴ for the whole brain. We used a Tukey's HSD test to determine whether this
136 group of DEGs (<1.5 TPM in adult brain cortex) displays a significantly different expression
137 profile between the brain developmental stages.

138 DEGs which are expressed <1.5 TPM in adult brain cortex but >1.5 RPKM in prenatal
139 stage of the whole brain and reach their maximum of expression in the prenatal stage were
140 selected and further analyzed for GO enrichment.

141 ***DEGs involved in NDDs***

142 A list of genes, which are known to play a role in NDDs, was obtained from PTEE¹⁴.
143 DEGs of 15q13.2q13.3 microdeletion patients were compared to the list of NDD genes, to
144 determine DEGs that could contribute to the neurological symptoms observed in those
145 patients. The significance for enrichment of DEGs with NDD genes was calculated using a
146 binomial test in R²⁵.

147 ***GO enrichment***

148 Gene ontology enrichment analysis was performed with the R package GOfuncR
149 (version 1.14.0) for up- and down-regulated DEGs²⁶. GO nodes with a family wise error rate
150 (FWER) <0.05 were considered significantly enriched. To check for unspecific GO
151 enrichment analysis results, the four control subjects were split in two groups and differential
152 gene expression and GO enrichment analyses were performed for those two control groups.

153 ***Identification of activated/inactivated DEG-interacted functional modules***

154 We investigated the activity of DEG-interacted functional modules to elucidate the
155 roles of DEGs in 15q microdeletion. The DEG-interacted network was constructed by the
156 DEGs and their interacting partners in the human protein interaction network (PIN), which
157 was obtained from the InBio Map database²⁷. A DEG-interacted functional module is a
158 subnetwork of the DEG-interacted network formed by genes annotated by the same biological
159 processes. The functional annotations of genes were obtained from GO^{28,29}, and only the
160 annotations supported by experiments were used in this study. Additionally, to ensure the
161 DEGs' participation and functional association among genes, all the functional modules were
162 required to contain at least one DEG and one interaction. To determine if the member genes
163 of the tested functional module were overrepresented at the top of the entire ranked gene list,
164 we performed the gene set enrichment analysis (GSEA)³⁰ for evaluating each module's
165 activity and inactivity separately. To assess the activity (inactivity), the entire gene list was
166 ranked downward (upward) by the fold change of genes between the 15q microdeletion and
167 controls. We then calculated the enrichment score (ES) for each functional module by
168 walking down the ranked gene list. The ES of functional module f is defined as below:

$$ES_f = \max(S_i), i \in \{1, \dots, N\}$$
$$S_i = \sum_{j=0}^i p \times \frac{1}{N_f} - (1-p) \times \frac{1}{(N-N_f)}, \text{ where } p = \begin{cases} 0 \\ 1, \text{ if gene } i \in f \end{cases}$$

169 where S_i is the score of gene i , i is ordered by fold change, N_f is the number of genes in
170 the tested functional module, N is the number of total ranked genes, and p is a binary
171 parameter. To estimate the significance of ES_f , we produced 1,000 scores ES_{rand} calculated
172 from 1,000 randomly permuted gene lists. Then, we denoted the standard score z , which was
173 defined as below, as the activity or inactivity of functional module f .

$$z = \frac{ES_f - \mu}{\sigma}$$

174 where μ and σ are respectively the mean and standard deviation of 1,000 ES_{rand} .
175 Finally, the functional modules possessing z of activity greater than two and z of inactivity
176 less than zero were defined as activated; and the functional modules with z of inactivity
177 greater than two and z of activity less than zero were defined as inactivated. The discovered
178 activated or inactivated functional modules were further summarized/clustered by the
179 REVIGO³¹ algorithm with similarity ≥ 0.9 that was calculated from Resnik³² algorithm and
180 visualized using the treemap package³³.

181 To predict key transcription factors and cofactors that drive transcriptomic differences
182 between microdeletion individuals and controls we used Mining Algorithm for GenetIc
183 Controllers (MAGIC), which leverages ENCODE ChIP-seq data to look for statistical
184 enrichment of transcription factors and cofactors in genes and flanking regions³⁴.

185 **Results**

186 *Transcriptional changes in 15q13.3 microdeletion individuals and Df[h15q13]/+ mice*

187 To study the effects of the 15q13.3 microdeletion on transcriptional regulation, we
188 performed RNA-seq from three individuals carrying a heterozygous 15q13.3 microdeletion
189 (Fig. 1) and four control subjects. Further, to identify robust changes across species and
190 tissues, we analyzed cerebral cortex tissue from ten mice (Df[h15q13]/+) reported by Gordon
191 *et al.*¹⁸. While in the 15q13.3 microdeletion subjects we identified 2,334 genes (adjusted *p*-
192 value < 0.05) with altered expression levels compared to controls (Supplementary Table S1),
193 only genes within the deleted region withstood multiple testing correction in the mouse
194 (Supplementary Table S1). This could be related to a difference in synteny between the
195 mouse and human chromosomal regions, to the high interindividual variability of our
196 subjects, or to the generally mild impact on gene expression with genes not reaching the
197 dysregulation threshold necessary to withstand conservative multiple testing correction. The
198 immediate result of applying multiple testing correction is that the probability a true effect
199 may be rejected will increase³⁵. To control for false positives, but also to avoid erroneously
200 rejecting real effects we decided to focus on DEGs shared between human and mouse. We,
201 thus, considered genes with uncorrected *p*-value < 0.05 in the mouse and identified 68 shared
202 genes between the two species and different tissues (Supplementary Table S1). To test
203 whether the number of overlapping genes is higher than expected by chance we performed
204 100,000 random samplings considering a total of 20,000 genes. This yielded a *p*-value of 0.02
205 suggesting the overlap is significant. By contrast, when we considered DEGs among controls,
206 only six genes were shared with the (Df[h15q13]/+) mouse model, which is an amount
207 expected to occur by chance (*p*-value=0.94 from 100,000 simulations).

208 To check whether the gene dosage affects gene expression, we identified genes located
209 in the deleted site, which are expressed in blood and brain cortex (Supplementary Fig. S1).
210 Four genes have an expression higher than 1.5 TPMs in brain cortex¹⁴ (*FANI*, *MTMR10*,
211 *KLF13*, *OTUD7A*) of which *MTMR10* and *KLF13* are also highly expressed in blood
212 (Supplementary Fig. S1). These genes were significantly downregulated in both human and
213 mouse samples (Supplementary Table S1). Moreover, although *FANI* and *OTUD7A* display
214 low expression levels in blood (Supplementary Fig. S1), they were also significantly
215 differentially expressed in our blood transcriptome analysis (Supplementary Table S1).

216 We next focused on shared DEGs between 15q13.3 microdeletion individuals and the
217 mouse model. Variants in eight of these genes (*PHIP*, *KAT6A*, *VPS13B*, *GPAA1*, *CHD7*,

218 *FIBP, KMT2C, AP1S1*) are known causes for monogenic NDD³⁶. There are six genes which
219 have a gene ontology (GO) annotation related to gene expression (*ZFP57, EDA, KAT6A,*
220 *CD46, PIK3R3*) and also six genes related to brain development (*CHD7, ITGA4, MYLIP,*
221 *PAFAH1B3, SIRT2, B4GALT2*). Interestingly, we could also identify components of the
222 major histocompatibility complex, class II to be dysregulated in both blood and brain
223 (Supplementary Table S1), which may reflect a disturbed inflammatory or immune process.

224 ***Molecular pathways affected by transcriptome alterations in 15q13.3 microdeletion***

225 To identify molecular pathways that may be affected by the gene expression profiles
226 we performed GO enrichment analysis followed by protein-protein-interaction (PPI)
227 networks, as previously described^{37,38}. Using the mouse data, we identified general GO
228 categories like cellular components or developmental processes to be enriched with DEGs
229 (Supplementary Table S2). For human subjects, there were two less general GO terms which
230 were most significantly enriched with DEGs: “nervous system development” (GO:0007399,
231 *p*-value after family wise error rate (FWER) multiple correction = 0.036) with 32 associated
232 genes and “DNA binding” (GO:0003677, *p*-value FWER multiple correction = 0.046) with
233 183 associated genes (Table 1, Supplementary Table S2).

234 To better delineate molecular pathways, involved in the copy-number variant (CNV)
235 pathomechanism, we further focused on identifying the functional modules formed by DEGs
236 from human subjects and their PPI partners. This revealed that most nodes clustered in
237 cellular processes like metabolic pathways, signaling, or cellular components (Fig. 2,
238 Supplementary Table S2). Since regulation of gene expression appeared to be perturbed, we
239 tested if the gene expression profile matches dysregulation of one or more transcription
240 factors based on ENCODE Chip-seq data³⁴. This analysis revealed no significant enrichment
241 for genes associated with a known transcription regulator, suggesting that a single gene
242 cannot explain the observed expression profile. Interestingly, inactivated functional modules
243 clusters are mainly involved in immune response and regulation of gene expression (Fig. 2B,
244 Supplementary Table S2). Oligodendrocyte differentiation and development appear to be
245 affected, which together with the “positive regulation of neuron death” (Fig. 2A, B,
246 Supplementary Table S2) could explain the impaired nervous system development. To check
247 whether those molecular pathways are specifically identified in the microdeletion individuals,
248 we analyzed differential gene expression between two control groups. GO terms significantly
249 enriched with DEGs of the control groups were mostly related to immune response, and to a
250 much lesser extent to gene expression regulation (Supplementary Table S2). Thus, the

251 identification of those molecular pathways in the individuals bearing 15q13.3 microdeletion
252 may not be related to the deleted region, but rather to the analyzed tissue. In contrast, we did
253 not identify any GO terms related to nervous system development in the controls. This
254 supports our hypothesis that the effect on pathways related to nervous system development in
255 the affected individuals is a result of the microdeletion.

256 We showed that affected genes were enriched in pathways related to nervous system
257 development (Table 1) and that PPIs influence apoptosis and neuron death (Fig. 2B). This
258 prompted us to inquire all DEGs that have known Mendelian associations with monogenic
259 NDD. We identified 252 of the DEGs to be related to monogenic intellectual disability (Fig.
260 2C, Supplementary Table S1). The number of genes is significantly higher than expected by
261 chance (p -value binomial test = 0.003), which could suggest an underlying polygenic effect
262 that leads to an increased risk for a neurodevelopmental disorder.

263 *Dysregulated genes in 15q13.3 microdeletion individuals expressed in the developing brain*

264 Further, we asked whether blood DEGs, which are not expressed in the adult brain
265 cortex, may have been expressed in the developing brain. We identified 358 DEGs, which are
266 expressed in blood but not in the adult brain. We used the ABAEnrichment package in R²⁴ to
267 check the expression levels of these genes during the different stages of brain development
268 (Supplementary Table S3). For 245 of the 358 genes, we could retrieve expression levels from
269 the Allen Brain Atlas. Our analysis revealed that for DEGs, which are silenced in the adult
270 brain, there is a significant enrichment for the ones with a maximum expression level in the
271 developing brain (p -value = 0.04, Fig. 3). A GO enrichment analysis of the 53 genes showed
272 that several of these genes are involved in chromosome organization during cell division, but
273 also identified the e.g. *DRAXIN* gene to be dysregulated, which is involved in the
274 development of spinal cord (Supplementary Table S3).

275 **Discussion**

276 The 15q13.3 microdeletion is associated with pleiotropic effects and has been
277 described in a wide spectrum of clinical contexts ranging from apparently healthy individuals
278 to some severely affected with ID, epilepsy or even schizophrenia (Fig. 1B)². It is difficult to
279 dissect the mechanisms contributing to the nervous system developmental disturbance mostly
280 because of the limitations of *in vitro* approaches aiming to reproduce human brain
281 development¹⁰. Thus, the etiology of the 15q13.3 microdeletion's range of hypervariable
282 symptoms remains elusive.

283 To understand how dysregulation of gene expression contributes to 15q13.3
284 microdeletion pathomechanisms, we aimed to circumvent artefacts introduced by
285 conventional *in vitro* approaches. Thus, we analyzed transcriptional profiles from three
286 individuals with 15q13.3 microdeletion in an *in vivo* state in blood, which is an easily
287 accessible tissue. To identify genes, which are robustly dysregulated we additionally analyzed
288 brain cortex tissue from a 15q13.3 microdeletion mouse model.

289 We initially checked for dosage effects of the genes included in the microdeletion
290 (Fig. 1A). This revealed that there are four genes with high expression in brain cortex
291 (Supplementary Fig. S1¹⁴): *FANI*, *MTMR10*, *KLF13*, *OTUD7A*, all of which showed
292 significant down-regulation in blood (Supplementary Table S1) of our subjects, as well as
293 mouse brain cortex, confirming that a gene dosage effect of the microdeletion contributes to
294 the transcriptional dysregulation. Other genes included in the typical deletion region: *TRPM1*,
295 *CHRNA7*, *MIR211*, *ARHGAP11B*, display low expression levels in brain cortex and blood
296 (Supplementary Fig. S1) and were not significantly differentially expressed in the 15q13.3
297 microdeletion individuals. While *MIR211* is a microRNA, which was not sequenced probably
298 as a result of the library preparation protocol and *ARHGAP11B* is a human specific gene³⁶,
299 *Trpm1* and *Chrna7* were down-regulated in mouse brain cortex (Supplementary Table S1),
300 further supporting the importance of the haploinsufficiency.

301 We next focused on dysregulated genes across the two different tissues in the human
302 subjects and the mouse model. One of the shared down-regulated genes is *CHD7*, which is
303 frequently associated with CHARGE syndrome and has been shown to be highly relevant for
304 neuronal differentiation and brain development³⁹. *CDH7*, but also other shared dysregulated
305 genes like *KMT2C* and *KAT6A* are involved in chromatin remodeling and hence in regulation
306 of gene expression. This is in accordance with the findings of Zhang *et al.*, who described a
307 global epigenomic reprogramming of iPSCs from 15q13.3 microdeletion individuals¹².
308 However, in their approach they were not able to identify driving factors, potentially
309 secondary to the bias induced by *in vitro* cultivation. This could also explain why they do not
310 identify any shared dysregulations with the mouse model and their multiomics approach
311 yielded a rather low correlation level among the multiple analyses.

312 To identify affected molecular pathways we performed a GO analysis of DEGs. This
313 showed a significant enrichment of DEGs that are involved in DNA binding (Table 1).
314 Moreover, an analysis of functional modules formed by DEGs and their PPI partners
315 confirmed that gene expression regulation is affected (Fig. 2B, Supplementary Table 2). Yet,

316 based on ENCODE data³⁴, we did not identify any transcription factor that could explain the
317 observed transcriptional profile. This is in accordance with the observation of Zhang *et al.*
318 that the disease-relevant impact of the 15q13.3 microdeletion is probably caused by the
319 combinatorial effects of several genes, rather than a single “master” gene. Our analysis
320 showed network-wide dysregulatory effects and explains why knockout models of singular
321 genes encompassed in the deletion could not fully recapitulate the phenotype³⁻¹⁰.

322 The GO analysis also revealed that DEGs show a significant enrichment in the
323 nervous system development category (Table 1). Indeed, we could show that the set of
324 dysregulated genes contained a significant proportion (p -value = 0.003) of genes which have
325 been related to monogenic NDD (Fig. 2C, Supplementary Table S1). The PPI functional
326 module analysis identified more specific developmental processes of the nervous system like
327 oligodendrocyte differentiation, axon and neuron projection development, as well as “positive
328 regulation of neuron death” to be affected (Fig. 2A, B, Supplementary Table S2). This aligns
329 with experimental data from Df[h15q13]/+ mice, which shows that both loss of *OTUD7A* and
330 *CHRNA7* contribute to dendrite outgrowth defects^{3,6}, and also with the recently described
331 involvement of *Klf13* in the development of cortical interneurons.¹⁰

332 To determine whether other DEGs silenced in the adult human brain might have
333 played a role in the nervous system development, we used the Allen Brain Atlas data, which
334 provides brain gene expression data during different developmental stages.²⁴ This showed
335 that a significant number of genes found to be differentially expressed in blood, but silenced
336 in the adult brain had maximum expression levels in the prenatal stage (Fig. 3).

337 Our data suggests that network-wide dysregulatory effects contribute to 15q13.3
338 microdeletion pathomechanisms. There are several lines of evidence that indicate a disturbed
339 nervous system development, suggesting the severity of 15q13.3 microdeletion individuals’
340 symptoms is probably determined in the early embryonic stages. The identification of
341 dysregulated genes clustering in inflammatory and immune pathways may be related to the
342 analyzed tissue, namely blood. However, since we identified components of the major
343 histocompatibility complex, class II to be dysregulated in the mouse brain, we cannot rule out
344 that immune insults could contribute to the increased vulnerability of 15q13.3 microdeletion-
345 bearing offspring.

346 A major limitation of our study is the small cohort, in which individual-characteristic
347 gene expression levels, which were not caused by the microdeletion, can have a big impact on
348 the analysis. We attempted to circumvent this by comparing our data to the mouse model.

349 However, a larger cohort and potentially the analysis of an additional tissue like skin, could
350 further refine the analysis and unveil which gene network is mostly responsible for the
351 pathomechanism. This is crucial for directing future efforts to minimize the severity of the
352 phenotype.

353 **Acknowledgements**

354 We are grateful that our patients and their families agreed to participate in this study.
355 We thank Sandra Schinkel, Kathleen Lehmann, and Sophie Behrendt for their great technical
356 assistance and Rigo Schulz for server support. We are grateful to Torsten Schöneberg for his
357 input and help to draw Fig. 1.

358 **Author contributions**

359 MK performed gene expression analyses, contributed to the design of the study and
360 writing of the manuscript. AV and LB supported bioinformatic analyses and performed GO
361 enrichment analyses. MR performed wet lab work and contributed to the design of the study.
362 CCL performed PPI analyses and contributed to manuscript writing. PZ recruited patients,
363 performed phenotyping, and coordinated the genetic diagnosis. TB, AT, KP, and JH
364 performed genetic diagnosis and contributed to the writing of the manuscript. AK, AM, NS,
365 TL, KP, JRL, and AG contributed to analysis design, data interpretation, and writing of the
366 manuscript. RAJ and DLD designed the study, coordinated the contact to patients, contributed
367 to genetic diagnosis, gene expression analysis, and writing of the manuscript.

368 **Funding**

369 This study is funded by the Else Kröner-Fresenius-Stiftung 2020_EKEA.42 to DLD
370 and the German Research Foundation SFB 1052 project B10 to DLD and AG. DLD is funded
371 through the “Clinician Scientist Programm, Medizinische Fakultät der Universität Leipzig”.
372 Open Access funding enabled and organized by Projekt DEAL.

373 **Data availability**

374 RNA sequencing reads and expression profiles have been submitted to the Gene
375 Expression Omnibus (<http://www.ncbi.nlm.nih.gov/geo/>) under accession number
376 GSE197903. The code used for analyzing data has been deposited under
377 <https://github.com/akhilvelluva/15q13.3>.

378

379

380 **References**

- 381 1. van Bon, B. W., Mefford, H. C. & de Vries, B. B. *15q13.3 Microdeletion*.
382 *GeneReviews*® (University of Washington, Seattle, 2015).
- 383 2. Lowther, C., Costain, G., Stavropoulos, D. J., Melvin, R., *et al.* Delineating the
384 15q13.3 microdeletion phenotype: A case series and comprehensive review of the
385 literature. *Genetics in Medicine* vol. 17 149–157 (2015).
- 386 3. Gillentine, M. A., Yin, J., Bajic, A., Zhang, P., *et al.* Functional Consequences of
387 CHRNA7 Copy-Number Alterations in Induced Pluripotent Stem Cells and Neural
388 Progenitor Cells. *Am. J. Hum. Genet.* **101**, 874–887 (2017).
- 389 4. Hoppman-Chaney, N., Wain, K., Seger, P. R., Superneau, D. W., *et al.* Identification of
390 single gene deletions at 15q13.3: Further evidence that CHRNA7 causes the 15q13.3
391 microdeletion syndrome phenotype. *Clin. Genet.* **83**, 345–351 (2013).
- 392 5. Yin, J., Chen, W., Chao, E. S., Soriano, S., *et al.* Otud7a Knockout Mice Recapitulate
393 Many Neurological Features of 15q13.3 Microdeletion Syndrome. *Am. J. Hum. Genet.*
394 **102**, 296–308 (2018).
- 395 6. Uddin, M., Unda, B. K., Kwan, V., Holzapfel, N. T., *et al.* OTUD7A Regulates
396 Neurodevelopmental Phenotypes in the 15q13.3 Microdeletion Syndrome. *Am. J. Hum.*
397 *Genet.* **102**, 278–295 (2018).
- 398 7. Ionita-Laza, I., Xu, B., Makarov, V., Buxbaum, J. D., *et al.* Scan statistic-based
399 analysis of exome sequencing data identifies FAN1 at 15q13.3 as a susceptibility gene
400 for schizophrenia and autism. *Proc. Natl. Acad. Sci. U. S. A.* **111**, 343–348 (2014).
- 401 8. Florio, M., Albert, M., Taverna, E., Namba, T., *et al.* Human-specific gene
402 ARHGAP11B promotes basal progenitor amplification and neocortex expansion.
403 *Science (80-.)*. **347**, 1465–1470 (2015).
- 404 9. Hori, T., Ikuta, S., Hattori, S., Takao, K., *et al.* Mice with mutations in *Trpm1*, a gene
405 in the locus of 15q13.3 microdeletion syndrome, display pronounced hyperactivity and
406 decreased anxiety-like behavior. *Mol. Brain* **14**, 1–16 (2021).
- 407 10. Malwade, S., Gasthaus, J., Bellardita, C., Andelic, M., *et al.* Identification of
408 Vulnerable Interneuron Subtypes in 15q13.3 Microdeletion Syndrome Using Single-
409 Cell Transcriptomics. *Biol. Psychiatry* (2021) doi:10.1016/j.biopsych.2021.09.012.

- 410 11. Nilsson, S. R. O., Celada, P., Fejgin, K., Thelin, J., *et al.* A mouse model of the
411 15q13.3 microdeletion syndrome shows prefrontal neurophysiological dysfunctions
412 and attentional impairment. *Psychopharmacology (Berl)*. **233**, 2151–2163 (2016).
- 413 12. Zhang, S., Zhang, X., Purmann, C., Ma, S., *et al.* Network Effects of the 15q13.3
414 Microdeletion on the Transcriptome and Epigenome in Human-Induced Neurons. *Biol.*
415 *Psychiatry* **89**, 497–509 (2021).
- 416 13. Solomon, E., Davis-Anderson, K., Hovde, B., Micheva-Viteva, S., *et al.* Global
417 transcriptome profile of the developmental principles of in vitro iPSC-to-motor neuron
418 differentiation. *BMC Mol. Cell Biol.* **22**, (2021).
- 419 14. Velluva, A., Radtke, M., Horn, S., Popp, B., *et al.* Phenotype-tissue expression and
420 exploration (PTEE) resource facilitates the choice of tissue for RNA-seq-based clinical
421 genetics studies. *BMC Genomics* **22**, 802 (2021).
- 422 15. Frésard, L., Smail, C., Ferraro, N. M., Teran, N. A., *et al.* Identification of rare-disease
423 genes using blood transcriptome sequencing and large control cohorts. *Nat. Med.* **25**,
424 911–919 (2019).
- 425 16. Curry, P. D. K., Broda, K. L. & Carroll, C. J. The Role of RNA-Sequencing as a New
426 Genetic Diagnosis Tool. *Curr. Genet. Med. Rep.* **9**, 13–21 (2021).
- 427 17. Zacher, P., Mayer, T., Brandhoff, F., Bartolomaeus, T., *et al.* The genetic landscape of
428 intellectual disability and epilepsy in adults and the elderly: a systematic genetic work-
429 up of 150 individuals. *Genet. Med.* **23**, 1492–1497 (2021).
- 430 18. Gordon, A., Forsingdal, A., Klewe, I. V., Nielsen, J., *et al.* Transcriptomic networks
431 implicate neuronal energetic abnormalities in three mouse models harboring autism and
432 schizophrenia-associated mutations. *Mol. Psychiatry* **26**, 1520–1534 (2021).
- 433 19. Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., *et al.* STAR: Ultrafast universal
434 RNA-seq aligner. *Bioinformatics* **29**, 15–21 (2013).
- 435 20. Anders, S., Pyl, P. T. & Huber, W. HTSeq-A Python framework to work with high-
436 throughput sequencing data. *Bioinformatics* **31**, 166–169 (2015).
- 437 21. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and
438 dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, (2014).
- 439 22. Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N., *et al.* Controlling the false discovery
440 rate in behavior genetics research. in *Behavioural Brain Research* vol. 125 279–284

- 441 (Behav Brain Res, 2001).
- 442 23. Marini, F. & Binder, H. PcaExplorer: An R/Bioconductor package for interacting with
443 RNA-seq principal components. *BMC Bioinformatics* **20**, (2019).
- 444 24. Grote, S., Prüfer, K., Kelso, J. & Dannemann, M. ABAEnrichment: An R package to
445 test for gene set expression enrichment in the adult and developing human brain.
446 *Bioinformatics* **32**, 3201–3203 (2016).
- 447 25. Team, R. C. R: A language and environment for statistical computing. (2013).
- 448 26. Grote, S. GOfuncR: Gene ontology enrichment using FUNC. *R Packag. version 1.5.1*
449 (2018).
- 450 27. Li, T., Wernersson, R., Hansen, R. B., Horn, H., *et al.* A scored human protein-protein
451 interaction network to catalyze genomic interpretation. *Nat. Methods* **14**, 61–64 (2016).
- 452 28. Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., *et al.* Gene ontology: Tool for
453 the unification of biology. *Nature Genetics* vol. 25 25–29 (2000).
- 454 29. Carbon, S., Douglass, E., Dunn, N., Good, B., *et al.* The Gene Ontology Resource: 20
455 years and still GOing strong. *Nucleic Acids Res.* **47**, D330–D338 (2019).
- 456 30. Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., *et al.* Gene set
457 enrichment analysis: A knowledge-based approach for interpreting genome-wide
458 expression profiles. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 15545–15550 (2005).
- 459 31. Supek, F., Bošnjak, M., Škunca, N. & Šmuc, T. Revigo summarizes and visualizes
460 long lists of gene ontology terms. *PLoS One* **6**, (2011).
- 461 32. Resnik, P. Semantic Similarity in a Taxonomy: An Information-Based Measure and its
462 Application to Problems of Ambiguity in Natural Language. *J. Artif. Intell. Res.* **11**,
463 95–130 (1999).
- 464 33. Tennekes, M. Package ‘treemap’ Type Package Title Treemap Visualization. (2021).
- 465 34. Roopra, A. MAgIC: A tool for predicting transcription factors and cofactors driving
466 gene sets using ENCODE data. *PLoS Comput. Biol.* **16**, e1007800 (2020).
- 467 35. Groenwold, R. H. H., Goeman, J. J. & Le Cessie, S. Multiple testing: When is many
468 too much? *Eur. J. Endocrinol.* **184**, E11–E14 (2021).
- 469 36. Xing, L., Kubik, Zahorodna, A., Namba, T., Pinson, A., *et al.* Expression of
470 human-specific ARHGAP11B in mice leads to neocortex expansion and increased

- 471 memory flexibility. *EMBO J.* **40**, (2021).
- 472 37. Jäger, E., Schulz, A., Lede, V., Lin, C.-C., *et al.* Dendritic Cells Regulate GPR34
473 through Mitogenic Signals and Undergo Apoptosis in Its Absence. *J. Immunol.* **196**,
474 2504–2513 (2016).
- 475 38. Le Duc, D., Lin, C. C., Popkova, Y., Yang, Z., *et al.* Reduced lipolysis in lipoma
476 phenocopies lipid accumulation in obesity. *Int. J. Obes.* **45**, 565–576 (2021).
- 477 39. Feng, W., Kawauchi, D., Körkel-Qu, H., Deng, H., *et al.* Chd7 is indispensable for
478 mammalian brain development through activation of a neuronal differentiation
479 programme. *Nat. Commun.* **8**, 1–14 (2017).
- 480 40. Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., *et al.* The mutational
481 constraint spectrum quantified from variation in 141,456 humans. *Nature* **581**, 434–443
482 (2020).

483

484

485 **Figure legends**

486 **Fig. 1.** Overview of the 15q13.3 locus and symptoms associated with the
487 microdeletion A. Schematic representation of the 15q13.3 microdeletion region. Protein
488 coding genes within the region are shown beneath chromosome 15. The color legend
489 corresponds to the pLI score as a measure of loss-of-function deleteriousness⁴⁰. Underlined
490 genes have been considered candidates that are responsible for the observed phenotypes
491 (*CHRNA7*^{3,4}, *OTUD7A*^{5,6}, *FANI*⁷, *ARHGAP11B*⁸, *TRPM1*⁹, *KLF13*¹⁰) B. Individuals with
492 15q13.3 microdeletion display a heterogenous phenotype which can range from normal
493 development to severe intellectual disability (ID) or neurodevelopmental disorders (NDD). A
494 delineation of the phenotype based on 246 cases revealed predominantly neurologic
495 symptoms of which ID, epilepsy, and neuropsychiatric disorders are most prominent².

496 **Fig. 2.** Functional modules representation. A. Activated functional modules clusters in
497 individuals with 15q13.3 microdeletion. Functions that could influence nervous system
498 development are clustered in oligodendrocyte differentiation under the “cellular
499 differentiation” category. The size of the boxes is proportional to the activation level of the
500 module. B. Inactivated functional modules clusters in individuals with 15q13.3 microdeletion.
501 These include processes relevant for neuron development. The size of the boxes is

502 proportional to the inactivation level of the module. C. 252 of the DEGs are related to
503 monogenic neurodevelopmental disorders (NDD). The number of genes is significantly
504 higher than expected by chance (p -value binomial test = 0.003).

505 **Fig. 3.** Inquiry of DEGs which are not expressed in the adult brain cortex. Based on
506 the Allen Brain Atlas these genes show a significant enrichment for genes with highest
507 expression level in the prenatal stage (p -value adult vs. prenatal stage = 0.04).

508


509 **Table 1.** Enriched overrepresented GO terms in DEGs of 15q13.3 individuals. FWER:
510 family-wise error rate corrected p -value; #genes: number of DEGs involved in the function.
511 For genes included in the nodes refer to Supplementary Table S2.

GO ID	Ontology	GO term	raw p -value	FWER	#genes
GO:0007399	biological process	nervous system development	1.93E-05	0.036	32
GO:0003677	molecular function	DNA binding	0.0001	0.046	183


512




513

A



B







Total=2,334 DEGs



- DEGs with brain cortex expression
- DEGs not expressed in brain cortex, with expression levels in Allen Brain Atlas
- DEGs not expressed in brain cortex, nor in Allen Brain Atlas





Supplementary Fig. S1. Expression levels of genes located in the 15q13.3 microdeletion region. TPM (transcript per kilobase million mapped reads) values of gene expression levels are depicted for brain cortex tissue and whole blood. The dashed lines represent 1.5 TPM. Expression values were obtained from PTEE (<https://bioinf.eva.mpg.de/PTEE/>).